A growth hormone blood test measures GH, also called somatotropin, but a single result rarely answers whether production is normal. GH is released by the pituitary in pulses, with long periods of very low or undetectable concentration between peaks. Exercise, sleep, fasting, stress, glucose, age, puberty, body composition, and illness all change secretion. For suspected deficiency, clinicians usually combine growth or pituitary history with IGF-1 and a supervised stimulation test. For suspected excess, an age-adjusted IGF-1 level is the main screening test, followed when needed by an oral glucose GH suppression test. A random GH value may still be useful in selected settings, such as monitoring established acromegaly or documenting a clearly elevated level, but it must be interpreted with the assay, timing, and clinical question. “High,” “low,” and “normal” therefore mean different things in a random sample, stimulation test, and suppression test.
- GH secretion is pulsatile, so a low random value is often normal.
- IGF-1 reflects average GH action more reliably than one GH measurement.
- Stimulation testing evaluates suspected GH deficiency.
- Glucose suppression testing evaluates suspected GH excess.
- Normal ranges and cutoffs vary by age, sex, body mass index, assay, and protocol.
- A result should be linked to symptoms, pituitary history, and related hormone tests.
Table of Contents
- What Growth Hormone Does
- Types of GH Tests
- Preparation and Sample Timing
- Normal Ranges and Cutoffs
- Low GH Results
- High GH Results
- Next Steps and Questions
What Growth Hormone Does
Growth hormone is produced by somatotroph cells in the anterior pituitary. The hypothalamus regulates its release through growth hormone-releasing hormone, somatostatin, and metabolic signals including ghrelin. Secretion occurs in bursts rather than at a steady rate.
In children, GH promotes linear growth through direct actions and by stimulating insulin-like growth factor 1, mainly in the liver and growth plates. It supports bone lengthening, protein synthesis, and tissue development. During puberty, sex steroids amplify GH secretion and IGF-1, producing the adolescent growth spurt.
In adults, GH continues to influence body composition, bone remodeling, lipid metabolism, muscle, exercise capacity, and quality of life. Normal secretion declines with age. This physiologic decline is not the same as adult growth hormone deficiency caused by hypothalamic or pituitary disease.
GH increases fat breakdown and opposes some insulin actions. During fasting or hypoglycemia, secretion can rise to preserve glucose for the brain and mobilize energy. Oral glucose normally suppresses GH. These physiologic responses form the basis of stimulation and suppression tests.
IGF-1 is a more stable marker of integrated GH action. It changes slowly and has age-specific reference intervals. A normal IGF-1 does not exclude every case of deficiency, and a high IGF-1 can be affected by puberty, pregnancy, liver function, nutrition, and assay issues, but it is generally more useful than random GH for initial screening.
The term “human growth hormone,” or HGH, is often used for both natural and manufactured hormone. Laboratory assays measure endogenous and exogenous GH to varying degrees depending on the product and method. Treatment monitoring usually relies on IGF-1 and clinical response rather than trying to reproduce a random GH range.
Types of GH Tests
The correct test depends on whether the concern is too little GH, too much GH, or treatment monitoring.
Random or Baseline GH
A random blood sample captures one moment in a pulsatile cycle. A low result cannot diagnose deficiency because healthy people spend much of the day with GH below the assay’s detection limit. A high result may reflect a normal pulse, exercise, fasting, stress, poor sleep, or hypoglycemia.
Random GH can contribute when it is repeatedly elevated with a high IGF-1, when a specialist is monitoring established acromegaly, or when a sample is collected under defined conditions. It is not a general wellness or anti-aging test.
GH Stimulation Test
A stimulation test evaluates pituitary reserve. After fasting, a medicine or metabolic challenge is given to provoke GH release, and samples are collected over time. Agents include insulin-induced hypoglycemia, glucagon, arginine, clonidine, and macimorelin in selected adult settings.
The highest concentration is the peak GH. A low peak supports deficiency only when the correct assay- and protocol-specific cutoff is used and the clinical probability is appropriate. The growth hormone stimulation test is more informative than a random level but still has imperfect reproducibility.
GH Suppression Test
An oral glucose load should suppress GH in people without autonomous GH excess. Blood is drawn before and at intervals after glucose. Failure to suppress to the validated nadir supports acromegaly when IGF-1 is elevated and clinical findings fit.
The test is described in detail in the growth hormone suppression test guide. Glucose intolerance, diabetes, estrogen status, and assay sensitivity can affect interpretation.
Serial or Overnight Sampling
Frequent sampling over several hours can characterize spontaneous secretion but is labor-intensive and rarely used for routine diagnosis. Sleep studies of GH are mainly research or specialized tools. Dynamic pharmacologic testing is generally more practical.
Monitoring on Treatment
During recombinant GH therapy, IGF-1, growth response, body composition, symptoms, glucose, and adverse effects guide dosing. A random GH level is not usually a target. In acromegaly, both IGF-1 and GH may be monitored because discordant results occur.
Preparation and Sample Timing
Preparation depends on the protocol. A random GH measurement may require no special preparation, but the reason for testing, time, recent exercise, food intake, stress, glucose, and medication use should be documented.
Dynamic tests commonly require an overnight fast. Water may be allowed according to the center’s instructions. Strenuous exercise, nicotine, and alcohol may be restricted beforehand because they can alter GH or glucose responses.
Patients should report:
- recombinant GH, long-acting GH, or IGF-1 therapy;
- estrogen, testosterone, glucocorticoids, or thyroid hormone;
- insulin and diabetes medicines;
- stimulants, opioids, and medicines affecting pituitary function;
- pregnancy;
- seizures, heart disease, adrenal insufficiency, or severe illness.
Do not stop hormone replacement without instructions. In a person with possible ACTH deficiency, adequate cortisol status must be established before an insulin tolerance test. Severe hypoglycemia is the intended stimulus in that test, so it is contraindicated in people with seizure disorders and certain cardiovascular conditions.
Glucagon stimulation can take several hours and may cause nausea, vomiting, or delayed hypoglycemia. Macimorelin is an oral ghrelin-receptor agonist used in adults in some regions; medicines that prolong the QT interval or interact with its metabolism require review.
For oral glucose suppression, the patient fasts and drinks a measured glucose solution. Samples are collected at protocol times, often over two hours. Vomiting, incomplete ingestion, or failure of glucose to rise can invalidate the challenge.
In children, puberty and sex-steroid priming may affect stimulation results. Some centers prime older prepubertal children with estrogen or testosterone before testing to reduce false-positive low peaks associated with constitutional delay. Practice varies, and the decision should be recorded.
Body mass index is particularly important in adults. Obesity blunts stimulated GH even without pituitary disease. Several adult tests use BMI-adjusted cutoffs. Undernutrition can produce higher GH with low IGF-1 because of GH resistance.
Assays are not interchangeable. Modern immunoassays use different antibodies and calibrators and may measure GH isoforms differently. A cutoff validated for one method cannot automatically be applied to another.
Conditions on the Day of Testing
Dynamic testing should be postponed when an acute illness, uncontrolled thyroid disorder, or unstable diabetes is likely to distort the response or make the procedure unsafe. A child who has eaten despite fasting instructions, vomits a stimulating medicine, or has an intravenous line that fails during critical sampling may need a rescheduled study rather than an interpretation based on incomplete data.
Sleep matters because the largest physiologic GH pulse often follows deep sleep. However, sleeping poorly before a pharmacologic test does not create a simple correction factor. The center records relevant circumstances and relies on the validated stimulus rather than trying to predict the spontaneous pulse.
For patients receiving long-acting GH, the interval from injection changes measured GH and IGF-1. The product’s monitoring recommendations specify when IGF-1 should be drawn. A random GH concentration after a dose mainly reflects pharmacokinetics and cannot be compared with an untreated reference interval.
Oral estrogen lowers hepatic IGF-1 generation and can make adults require a higher GH replacement dose than those using transdermal estrogen. Starting or stopping estrogen can therefore change IGF-1 without a new pituitary lesion. Testosterone, thyroid hormone, glucocorticoids, and nutritional recovery can also alter the axis.
A high-quality report should list the stimulus, dose, sample times, GH values, peak or nadir, glucose response, assay, and applicable cutoff. Without these details, a statement such as “failed GH test” cannot be independently reviewed and may lead to unnecessary repeat testing.
Normal Ranges and Cutoffs
A laboratory may report a random reference interval, but this interval has limited diagnostic value. Example adult random ranges may extend from near the detection limit to several nanograms per milliliter and may be higher in women than men. Children and adolescents can have much higher physiologic peaks, especially during puberty.
GH is commonly reported as ng/mL or µg/L; these units are numerically equivalent. The result must be matched to the test type.
| Test context | How “normal” is judged |
|---|---|
| Random GH | Laboratory interval, but low values do not exclude normal secretion |
| Pediatric stimulation | Peak above the center’s assay-specific threshold; often around 7–10 ng/mL historically |
| Adult insulin tolerance | Peak above a protocol cutoff, often approximately 3–5 ng/mL depending on method |
| Adult glucagon stimulation | BMI- and protocol-adjusted peak threshold |
| Macimorelin | Peak compared with the validated assay-specific cutoff |
| Oral glucose suppression | GH falls below the validated nadir, often below 1.0 ng/mL and with ultrasensitive assays below about 0.4 ng/mL |
These figures are examples, not universal diagnostic boundaries.
A normal random GH can occur in acromegaly if the sample is drawn during a trough. A high random GH can occur in a healthy person during a pulse. The most important “normal range” for screening excess is the age-adjusted IGF-1 interval.
For pediatric deficiency, older protocols often used 10 ng/mL as the normal stimulation threshold. Newer assays read lower, and many centers use 7 ng/mL, 5 ng/mL, or an agent-specific value. Applying the historical cutoff to a modern assay increases false-positive diagnoses.
For adult deficiency, cutoffs differ by stimulus and BMI. The insulin tolerance test remains a reference method when safe. Glucagon thresholds are often lower in people with obesity because their physiologic response is blunted. Macimorelin has its own validated cutoff and assay requirements.
For acromegaly, consensus interpretation emphasizes age-normalized IGF-1. In a patient with typical features and IGF-1 more than 1.3 times the upper limit of normal, the diagnosis may be established in the appropriate setting without relying on one random GH. An oral glucose test is useful when findings are equivocal or confirmation is needed.
Discordance is possible. IGF-1 can be high while GH appears controlled, or GH can be above a target while IGF-1 is normal. Assay variation, timing, estrogen, liver disease, kidney disease, diabetes, nutrition, and treatment type should be reviewed before changing management.
Reference intervals also describe a population, not an individual diagnostic probability. A result just outside the interval may be less important than a consistent trend accompanied by characteristic clinical change. Conversely, a result inside a broad random interval cannot override poor growth, a structural pituitary lesion, or a clearly abnormal dynamic response. Clinicians should compare serial IGF-1 values using age-adjusted SDS and keep the original assay in mind when a laboratory changes platforms.
In pregnancy, placental GH gradually replaces pituitary GH in the circulation and many routine assays behave differently. Standard acromegaly and deficiency cutoffs are not applied without specialist interpretation. In adolescence, physiologic GH and IGF-1 peaks are higher than in adults, making adult ranges inappropriate.
Low GH Results
A low random GH is usually not abnormal. Between secretory pulses, values may be undetectable even in healthy children and adults. The laboratory flag should not be interpreted as proof of pituitary failure.
Growth hormone deficiency is considered when clinical risk and dynamic testing agree. In children, clues include reduced height velocity, crossing percentiles, delayed bone age, relatively preserved weight, neonatal hypoglycemia, micropenis, midline abnormalities, cranial radiation, or other pituitary deficits. Testing also evaluates nutrition, thyroid disease, celiac disease, chronic inflammation, and genetic growth disorders.
In adults, deficiency usually follows a pituitary tumor, surgery, radiation, head injury, infiltrative disease, or congenital disorder. Symptoms such as low energy, increased abdominal fat, reduced muscle, low bone density, and poor quality of life are nonspecific. Adult-onset idiopathic GH deficiency without another explanation is uncommon.
A low stimulated peak may be caused or exaggerated by:
- obesity;
- inadequate stimulus or sampling;
- recent illness;
- hypothyroidism;
- low sex-steroid state or delayed puberty;
- glucocorticoid exposure;
- assay and cutoff mismatch.
IGF-1 helps frame the result. Low IGF-1 supports deficiency when nutrition, liver function, thyroid status, and systemic illness are adequate. Normal IGF-1 makes severe deficiency less likely but does not completely exclude it, especially in adults with strong pituitary risk factors.
Multiple pituitary deficits and structural abnormalities increase diagnostic confidence. A person with a pituitary lesion plus three or more other pituitary hormone deficiencies may sometimes be diagnosed without a provocative test under specialist guidelines. A child with classic congenital imaging and multiple deficits may also avoid stimulation.
Treatment is recombinant GH when benefits outweigh risks. Children are monitored for growth velocity and pubertal development. Adults are monitored for symptoms, body composition, IGF-1, glucose, lipids, bone health, and edema. Doses are individualized; more is not better.
A low GH result should never be used to justify nonprescribed “anti-aging” therapy. GH can cause edema, joint pain, carpal tunnel symptoms, insulin resistance, and other adverse effects, and it is not approved to reverse normal aging.
High GH Results
A high random value may be physiologic. Exercise, fasting, stress, sleep, hypoglycemia, puberty, and estrogen can increase secretion. The first step is usually to repeat or reframe the evaluation with IGF-1 rather than diagnose excess from one sample.
Persistent GH excess causes gigantism before growth plates close and acromegaly after closure. Most cases result from a GH-secreting pituitary adenoma. Rare causes include ectopic growth hormone-releasing hormone production and genetic syndromes.
Features of acromegaly develop gradually and may include enlargement of hands and feet, increased ring or shoe size, coarser facial features, jaw growth, wider tooth spacing, oily skin, sweating, headaches, snoring or sleep apnea, carpal tunnel symptoms, joint pain, hypertension, diabetes, and changes in menstrual or sexual function.
An elevated age-adjusted IGF-1 is the primary biochemical signal. The result should be repeated when unexpected and reviewed for pregnancy, adolescence, assay interference, liver disease, kidney disease, malnutrition recovery, and diabetes. Once excess is confirmed, pituitary MRI locates the lesion.
During oral glucose testing, healthy GH secretion suppresses. Failure to suppress below the assay-specific nadir supports acromegaly. A cutoff below 1.0 ng/mL has long been used, while sensitive modern assays may use below about 0.4 ng/mL. The laboratory and endocrine center’s validated threshold matters.
High GH with low IGF-1 can occur in undernutrition, uncontrolled type 1 diabetes, liver disease, critical illness, and GH resistance. This pattern does not indicate acromegaly. The liver is unable to generate the expected IGF-1 response despite increased GH.
After acromegaly treatment, GH and IGF-1 are followed over time. Surgery may produce rapid GH decline, while IGF-1 takes longer to stabilize. Medical therapies affect the relationship differently. Somatostatin analogues reduce secretion, pegvisomant blocks GH action and makes GH measurement unsuitable for monitoring, and dopamine agonists may lower both in selected patients.
Very high GH in a person using prescribed or nonprescribed hormone may reflect recent dosing. The exact product, dose, timing, and assay cross-reactivity should be documented. Testing for sports-doping purposes follows specialized chain-of-custody and biomarker protocols, not routine clinical interpretation.
Next Steps and Questions
The next step depends on the original question, not merely the direction of the flag.
For possible deficiency, clinicians review growth data or adult pituitary history, measure IGF-1, assess other pituitary hormones, and select an appropriate stimulation test. Pituitary MRI is performed when biochemical evidence, neurologic symptoms, or multiple deficits suggest structural disease.
For possible excess, age-adjusted IGF-1 is confirmed, glucose suppression is used when needed, and pituitary MRI follows biochemical diagnosis. Visual-field testing is added when a mass approaches the optic chiasm.
Laboratory questions to clarify include:
- Was this a random, stimulated, or suppressed sample?
- Which assay and cutoff were used?
- What were glucose, timing, and symptoms during the test?
- Does body mass index alter the stimulation threshold?
- Was the child prepubertal, pubertal, or sex-steroid primed?
- What was the age-adjusted IGF-1 at the same time?
- Could nutrition, thyroid disease, liver disease, kidney disease, diabetes, estrogen, or medication affect the result?
- Is repeat testing needed before imaging or treatment?
- Are other pituitary hormones abnormal?
Seek urgent assessment for sudden severe headache, new visual loss, double vision, vomiting, fainting, confusion, or weakness because pituitary apoplexy or adrenal insufficiency can present this way. A child with recurrent severe hypoglycemia also needs prompt evaluation.
During GH treatment, urgent review is warranted for severe headache with vomiting or visual symptoms, new limp or hip pain, marked swelling, breathing problems, or symptoms of high blood glucose. During acromegaly care, worsening vision or sudden headache requires rapid assessment.
The most accurate interpretation begins by naming the test context. “GH 0.2 ng/mL” can be entirely normal as a random trough, abnormal after adequate stimulation, and irrelevant during suppression testing. The number only becomes meaningful when the physiologic question and protocol are known.
A result should also be compared with the exact clinical question. A test designed to prove deficiency cannot be interpreted with the same threshold or physiology as a suppression test for hormone excess.
References
- Growth Hormone Tests 2024 (Patient and Laboratory Reference)
- Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis 2023 (Review)
- A 2024 Update on Growth Hormone Deficiency Syndrome in Adults: From Guidelines to Real Life 2024 (Review)
- Adult Growth Hormone Deficiency- Clinical Management 2022 (Clinical Review)
- Growth hormone test 2026 (Clinical Reference)
- Disorders of Growth Hormone in Childhood 2022 (Clinical Review)
Disclaimer
This article provides general education and cannot diagnose growth hormone deficiency, acromegaly, or another pituitary disorder. GH results are test-, assay-, age-, and protocol-specific and must be interpreted with IGF-1, clinical history, and related pituitary testing. Do not use or change growth hormone treatment based on a random result without specialist guidance.
